Full-year EBITDA guidance cut to $11-14 million vs. prior guidance of $11-16 million (7.4% downgrade at the midpoint) Full-year revenue guidance cut to $260-270 million vs. prior guidance of $280-290 ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong device growth. US device growth: “Global device sales were driven by ...

For a detailed explanation of Carl's technical analysis methodology, be sure to check out this ChartWatch Primer. Carl has over 30-year's investing experience, helping investors navigate several bull ...

IBM (+13.0%) beats forecasts amid surge in AI software and consulting revenue, Q2 EPS of $3.92 was well-ahead of $3.78 consensus (BBG) Tesla (+2.8%) Q4 profit misses on weaker-than-expected gross ...

After the result, Barrenjoey upgraded their target price by 18% to $3.30.

Fenix Resources aims to triple iron ore production to 4Mtpa in FY25 while leveraging its logistics network for growth Bell Potter is Buy rated on the stock with a 41 cent target and forecasts 5-6% ...

These are the ASX companies and sectors making headlines in afternoon trade. Alterity Therapeutics (ASX: ATH) – Shares surged 100% after the clinical-stage biotech company announced positive results ...

Zip shares plunged over 20% after Q2 earnings missed expectations, with weaker ANZ revenue yields and cash EBTDA falling short of analyst forecasts Despite the selloff, Zip's US business showed strong ...

Boss Energy's December quarter uranium production exceeded expectations by 36-75%, with its Honeymoon project ramping up and Alta Mesa on track for full capacity by 2026 Cost control surprised ...